| Mepolizumab |  | Placebo |
---|---|---|---|
ITT population | |||
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 335/466 (72) |  | 256/465 (55) |
 Odds ratio (mepolizumab/placebo), 95% CI; p-value |  | 2.17 (1.63, 2.87); p < 0.001 |  |
Age at asthma onset: < 18 years | |||
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 90/130 (69) |  | 65/122 (53) |
 Odds ratio (mepolizumab/placebo), 95% CI |  | 1.95 (1.12, 3.38) |  |
Age at asthma onset: 18–< 40 years | |||
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 123/173 (71) |  | 96/171 (56) |
 Odds ratio (mepolizumab/placebo), 95% CI |  | 2.17 (1.34, 3.51) |  |
Age at asthma onset: ≥ 40 years | |||
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 121/162 (75) |  | 95/172 (55) |
 Odds ratio (mepolizumab/placebo), 95% CI |  | 2.80 (1.70, 4.62) |  |
Lung function: ≤ 60% predicted FEV1 | |||
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 171/243 (70) |  | 132/242 (55) |
 Odds ratio (mepolizumab/placebo), 95% CI |  | 2.13 (1.44, 3.16) |  |
Lung function: > 60–80% predicted FEV1 | |||
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 137/177 (77) |  | 98/176 (56) |
 Odds ratio (mepolizumab/placebo), 95% CI |  | 3.03 (1.84, 4.99) |  |
Lung function: ≥ 80% predicted FEV1 | |||
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 27/46 (59) |  | 26/47 (55) |
 Odds ratio (mepolizumab/placebo), 95% CI |  | 2.12 (0.70, 6.48) |  |